LTR Pharma surpasses 1,000 SPONTAN® prescriptions under TGA Special Access Scheme

LTR Pharma (ASX:LTP) has reached an important milestone with SPONTAN® with more than 1,000 prescriptions now issued in Australia through the TGA Special Access Scheme.  

Prescribing under the TGA Special Access Scheme has included an expanding group of clinicians, particularly those managing complex erectile dysfunction cases, including prostate cancer patients and men with inadequate response to oral PDE5 therapies.   

Real-world prescribing insights from Australia are helping inform the US commercial strategy ahead of the planned ROXUS® launch in H1 CY2026. 

LTR Pharma Scientific Advisory Board member, Professor Eric Chung, said: 

"As clinicians, we frequently encounter patients who have not responded adequately to oral ED therapies or prefer a faster onset of action to allow for sexual spontaneity. SPONTAN's intranasal delivery system offers a meaningful alternative for these patients, and reaching 1,000 prescriptions under SAS reflects growing clinical demand for new and alternative treatment options in this space." 

Click to read the ASX release.